Duration of equine influenza virus shedding and infectivity in immunised horses after experimental infection with EIV A/eq2/Richmond/1/07
Introduction
Equine influenza (EI) is a major respiratory disease of horses induced by the highly contagious equine influenza virus (EIV) (Landolt et al., 2007). Recent EI outbreaks in countries previously considered EI-free (South Africa, Australia and Japan, Guthrie et al., 1999, Moloney, 2011, Yamanaka et al., 2008) highlight the importance of effective, science-based quarantine and associated testing practices to prevent the international spread of this important pathogen. EI remains a considerable impediment to ease of movement of horses internationally, although, the development of rapid and sensitive diagnostic tests, such as quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) assays offer the prospect of improved prevention of international spread of EIV.
Since the 2007 Australian EI outbreak, exportation of horses to Australia requires a 14 day pre-export quarantine period (PEQ), and 14–21 days post-arrival quarantine periods (PAQ), depending on whether or not all animals originate from the same PEQ, respectively. Such procedures are necessary to prevent infectious diseases outbreaks. However, several problems are associated with the combined duration of PEQ and PAQ, especially with competition and breeding horses. Racing, other competition or breeding opportunities may be lost and horses need to be kept in race training to maintain fitness. In addition, horses are sampled and tested by EIV qRT-PCR at least 4 times during combined PEQ and PAQ before being released. Equine influenza virus detection by qRT-PCR is highly sensitive and was extensively used during the 2007 Australian EI outbreak. It has also more recently been routinely used for EIV surveillance worldwide.
This study aimed to evaluate several different diagnostic testing methodologies currently in use, in order to provide a scientific evidence base for optimising current quarantine procedures for preventing international spread of EIV. The objectives of the study were:
- (1)
To compare nasal and nasopharyngeal swabs for detection of EIV in ponies experimentally infected with A/eq/Richmond/1/07. This objective aimed to compare the efficiency of nasal swabbing, which is better tolerated by the horses, with the conventional nasopharyngeal swabbing.
- (2)
To evaluate the duration of detectable levels of virus shedding, up to 28 days after experimental EI infection with EIV. Infectious EIV shedding is usually detectable in nasopharyngeal secretions for 7–10 days following infection using new methods, such as the EIV NP qRT-PCR, which present a higher sensitivity of detection. This objective aimed to improve current knowledge of the kinetics of EIV shedding in order to inform decision making regarding the duration of quarantine periods.
- (3)
To correlate the levels of virus shedding detected by standard methods (with diverse levels of sensitivity) in vaccinated animals with actual EIV infection of naïve sentinel ponies. This objective aimed to determine infectivity thresholds.
Section snippets
Experimental animals and vaccination protocol (Fig. 1)
This study was organised in to 3 modules in order to achieve the 3 main objectives described above.
Module 1: Seven EIV seronegative Welsh mountain ponies (aged 5–6 months at the time of first vaccination), were recruited to the study population. Two of these ponies (#N1 and #N2) remained as unvaccinated controls throughout the study. Five ponies (#V1–#V5) were immunised at day 0 (V1) and day 42 (V2) with an ISCOM-based EI vaccine (Equip™ FT; Pfizer Limited) containing antigens from the strains
SRH antibody response (Table 1)
All vaccinated ponies were seronegative for EIV prior to the first immunisation. Two weeks after V2, the mean SRH antibody levels were 98.7 ± 8.5, 95.8 ± 9 and 117.4 ± 11.8 mm2 against A/eq/Borlängle/91, A/eq/Kentucky/98 and A/eq/Richmond/1/07, respectively. Prior to experimental infection (D113, V2 + 71 days), vaccinated ponies showed low or negative SRH antibody levels. All naïve and sentinels ponies were seronegative for EIV prior to experimental infection or commingling. All study ponies showed
Discussion
Detection of virus shedding is absolutely essential to quarantine practice, especially as vaccinated horses may become infected and develop a subclinical, or very mild form of the disease but still shed low quantities of virus for a limited duration. In this context, NPS and NS swabbing was compared. Unfortunately, the use of NS swabs, which are better tolerated by the horses, were clearly demonstrated to be less efficient than NPS swab for detection of virus shedding. This was particularly
Acknowledgement
The authors would like to acknowledge the staff of the Equine Resources (Animal Health Trust), for excellent care of the ponies. The study was sponsored by Racing Victoria Ltd, Thoroughbred Breeders Australia, Harness Racing Australia, Equestrian Australia and International Racehorse Transport. R.P, L.P., F.M., R.N. and J.G. report no conflict of interest. B.S. and L.J. are employed by the study sponsors.
References (33)
- et al.
Antigenic and genetic variations in European and North American equine influenza virus strains (H3N8) isolated from 2006 to 2007
Vet. Microbiol.
(2009) - et al.
Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines
Vaccine
(2004) - et al.
A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt Horses – a randomised blind study
Vaccine
(2011) - et al.
A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings – a randomised blind study
Vaccine
(2011) - et al.
The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap
Vaccine
(2009) - et al.
Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95)
Vet. J.
(2004) - et al.
Equine influenza infection
- et al.
Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines
Vaccine
(1994) - et al.
Vaccination against equine influenza: quid novi?
Vaccine
(2006) - et al.
Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus
Vet. Immunol. Immunopathol.
(2006)